August 5th 2020
Christian U. Blank, MD, PhD, discusses the future of baseline biomarkers in macroscopic stage 3 melanoma.
July 30th 2020
The FDA has approved atezolizumab (Tecentriq) in combination with cobimetinib (Cotellic) and vemurafenib (Zelboraf) in the treatment of patients with BRAF V600 mutation–positive advanced melanoma.
As new data emerge in the melanoma treatment paradigm, new questions have come to light regarding neoadjuvant/adjuvant strategies, reduced dosing for immunotherapy combinations, and approaches following progression on, or resistance to, PD-1 inhibition.
July 28th 2020
Isabella C. Glitza Oliva, MD, PhD, MS, discusses the prognosis of patients with melanoma brain and/or central nervous system metastases.
July 27th 2020
Pembrolizumab was found to prolong survival in patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior administration of a BRAF inhibitor with or without a MEK inhibitor.
July 24th 2020
Sunandana Chandra, MD, MS, discusses unanswered questions regarding the utility of targeted therapy in melanoma.
July 23rd 2020
Richard L. Shapiro, MD, discusses the utility of complete lymph node dissection in melanoma.
July 21st 2020
Sunandana Chandra, MD, MS, discusses the incidence of targetable mutations in melanoma.
July 15th 2020
Jason J. Luke, MD, FACP, discusses the future of T-cell therapy in melanoma.
July 10th 2020
Immunotherapy and BRAF plus MEK inhibition are the key players in the treatment of patients with melanoma, Michael Postow, MD, said in a presentation during the 2020 ASCO Direct Highlights webcast.
